ALX Oncology Validates CD47 Biomarker Strategy, Raises $150M to Extend Runway — ALX Oncology Holdings Inc.

Event summary

ALX Oncology validated its CD47 biomarker strategy for evorpacept in gastric cancer and breast cancer trials, showing predictive response in HER2-positive patients.
The Phase 2 ASPEN-09-Breast trial is expanding enrollment to up to 120 patients, with topline data expected mid-2027.
ALX Oncology completed a $150 million equity offering, extending its cash runway through 1H 2028.
Barbara Klencke, M.D., was appointed as permanent Chief Medical Officer.

The big picture

ALX Oncology's validation of the CD47 biomarker strategy strengthens its position in the immuno-oncology space, particularly for HER2-positive cancers. The $150 million equity offering provides a substantial cash buffer, allowing the company to focus on key clinical milestones. The strategic focus on biomarker-driven clinical development aligns with broader industry trends toward precision medicine and targeted therapies.

What we're watching

Biomarker Validation: How the validation of CD47 as a predictive biomarker for evorpacept will impact the design and outcomes of future clinical trials.
Clinical Development: Whether ALX Oncology can sustain the momentum in its clinical programs for evorpacept and ALX2004, given the extended cash runway.
Execution Risk: The pace at which ALX Oncology can deliver meaningful data readouts from its ongoing clinical trials, particularly the Phase 2 ASPEN-09-Breast trial.